Dashboard
Manage Tickers

VYNE


()    

CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ ()
DIA ()
SPY ()
TLT ()
GLD ()
$ na
-- x --
-- x --
-- - --
-- - --
--
na
--
--
--
TBD
--
-- (--)
--
TBD --
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
No Data found
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
09/12/2024 15:33:19

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-announces-phase-1a-sad-data-for-vyn202-a-novel-bd2-selective-bet-inhibitor-vyn202-was-generally-well-tolerated-with-no-drug-related-adverse-events
VYNE Therapeutics Announces Phase 1a SAD D...
09/12/2024 12:13:02

VYN202 was generally well tolerated with no drug-related adverse events Pharmacokinetic results demonstrated dose-dependent exp...

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
08/15/2024 09:57:30

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-q2-2024-gaap-eps-022-misses-019-estimate-sales-198000k-beat-110000k-estimate
VYNE Therapeutics Q2 2024 GAAP EPS $(0.22)...
08/14/2024 12:07:27

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.22) per share which missed the analyst consensus estimate of $...

vyne-therapeutics-announces-composition-of-matter-patent-for-its-vyn202-bd2-selective-bet-inhibitor
VYNE Therapeutics Announces Composition Of...
07/16/2024 12:05:42

12-health-care-stocks-moving-in-thursdays-intraday-session
12 Health Care Stocks Moving In Thursday's...
06/20/2024 16:32:10

analyst-scoreboard-4-ratings-for-vyne-therapeutics
Analyst Scoreboard: 4 Ratings For VYNE The...
06/14/2024 13:01:32

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
06/14/2024 10:01:57

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-doses-first-volunteers-in-phase-1a-trial-of-vyn202-oral-bet-inhibitor-targeting-immuno-inflammatory-diseases-top-line-data-expected-in-h2-2024
VYNE Therapeutics Doses First Volunteers I...
06/13/2024 13:04:50

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
06/05/2024 15:21:26

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-doses-first-subject-in-phase-2b-vitiligo-trial-of-vyn201
VYNE Therapeutics Doses First Subject In P...
06/05/2024 12:01:46

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
05/09/2024 15:27:59

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

vyne-therapeutics-q1-eps-015-beats-024-estimate-sales-9800k-miss-10000k-estimate
VYNE Therapeutics Q1 EPS $(0.15) Beats $(0...
05/09/2024 13:06:19

VYNE Therapeutics (NASDAQ:VYNE) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0...

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
05/06/2024 14:45:06

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

12-health-care-stocks-moving-in-mondays-pre-market-session
12 Health Care Stocks Moving In Monday's P...
05/06/2024 12:06:38

vyne-therapeutics-announces-fda-clearance-of-ind-application-for-vyn202
VYNE Therapeutics Announces FDA Clearance ...
05/06/2024 12:04:29

vyne-therapeutics-presents-vyn201-at-2024-sid-annual-meeting
VYNE Therapeutics Presents VYN201 At 2024 ...
05/01/2024 12:45:19

Presentations will highlight positive preclinical and Phase 1b data of novel BET inhibitor, VYN201, in nonsegmental vitiligo

12-health-care-stocks-moving-in-fridays-after-market-session
12 Health Care Stocks Moving In Friday's A...
03/29/2024 20:30:47

hc-wainwright--co-reiterates-buy-on-vyne-therapeutics-maintains-575-price-target
HC Wainwright & Co. Reiterates Buy on VYNE...
02/29/2024 20:06:04

HC Wainwright & Co. analyst Joseph Pantginis reiterates VYNE Therapeutics (NASDAQ:VYNE) with a Buy and maintains $5.75 p...

recap-vyne-therapeutics-q4-earnings
Recap: VYNE Therapeutics Q4 Earnings
02/29/2024 13:30:06

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION